Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 2Not yet recruiting 1No longer available 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1

Interventions

Injections 41Carboplatin 34Cisplatin 24Capecitabine 24Paclitaxel 23Docetaxel 23pembrolizumab 21Oxaliplatin 21Gemcitabine 20Pemetrexed 19Bevacizumab 18Fluorouracil 13Irinotecan 12Cyclophosphamide 12osimertinib 9Nivolumab 8Dexamethasone 8tislelizumab 7Topotecan 7Leucovorin 7Doxorubicin 7130-nm albumin-bound paclitaxel 7venetoclax 6toripalimab 6regorafenib 6lenvatinib 6fludarabine 6Rituximab 6Cetuximab 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × sugemalimab × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡